Strategies to address drug interaction potential for antibody-drug conjugates in clinical development

Bioanalysis

Volumn 5, Issue 9, 2013, Pages 1115-1130

  Lu, Dan ^a   Sahasranaman, Srikumar ^a   Zhang, Yi ^a   Girish, Sandhya ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; CYCLOSPORIN DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOCETAXEL; DOFEQUIDAR; GEMTUZUMAB OZOGAMICIN; INOTUZUMAB OZOGAMICIN; PACLITAXEL; PCS 833; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; BREAST CANCER; DRUG CLEARANCE; DRUG COMPETITION; DRUG CYTOTOXICITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HODGKIN DISEASE; HUMAN; IC 50; LARGE CELL LYMPHOMA; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; NONHUMAN; PREDICTION; REVIEW; RISK ASSESSMENT; SENSORY NEUROPATHY; THROMBOCYTOPENIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; IMMUNOCONJUGATES; RISK ASSESSMENT;

EID: 84877285215     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.76     Document Type: Review

References (64)

1. Prabhu S, Boswell CA, Leipold D et al. Antibody-based delivery of small molecule cytotoxic drugs and radionuclides for cancer therapy-factors influencing clinical pharmacology. Ther. Deliv. 2(6), 769-791 (2011).
2. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 14(3), 154-169 (2008).
3. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr. Opin. Chem. Biol. 13(3), 235-244 (2009).
4. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 4(1), 98-107 (2008).
5. Teicher BA, Doroshow JH. The promise of antibody-drug conjugates. N. Engl. J. Med. 367(19), 1847-1848 (2012).
6. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15-29 (2013).
7. Singh Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer prodrug and conjugate design. Curr. Med. Chem. 15(18), 1802-1826 (2008).
8. Lu D, Burris HA 3rd, Wang B et al. Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. Curr. Drug Metab. 13(7), 911-922 (2012).
9. Lu D, Agarwal P, Prabhu S et al. Pharmacokinetics of anti-CD22 and anti-CD79b antibody drug conjugates in relapsed or refractory B-cell non-Hodgkin's lymphoma patients: results from phase I dose-escalation studies. Presented at: American Society of Clinical Pharmacology and Therapeutics Annual Meeting. Indianapolis, IN, USA, 5-9 March 2013.
10. Hughes B. Antibody-drug conjugates for cancer: poised to deliver? Nat. Rev. Drug Discov. 9(9), 665-667 (2010).
11. ADCETRIS™ (brentuximab vedotin), package insert. Seattle Genetics, Inc., Bothell, WA, USA.
12. Girish S, Gupta M, Wang B et al. Clinical pharmacology of T-DM1: a novel antibody-drug conjugate (ADC) in development for the treatment of HER2 positive (HER2+) cancer. Cancer Chemother. Pharmacol. 69(5), 1229-1240 (2012).
13. Advani A, Coiffier B, Czuczman MS et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a Phase I study. J. Clin. Oncol. 28(12), 2085-2093 (2010).
14. Fenton C, Perry CM. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia. Drugs 65(16), 2405-2427 (2005).
15. Bross PF, Beitz J, Chen G et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7(6),1490-1496 (2001).
16. Lin K, Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res. 29(9), 2354-2366 (2012).
17. Kaur S, Xu K, Saad O et al. A perspective on bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 5(2), 201-226 (2013).
18. Lu D, Joshi A, Wang B et al. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. Clin. Pharmacokinet. (2013) (in press).
19. Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363(19), 1812-1821 (2010).
20. Shen B-Q, Bumbaca D, Saad O et al. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr. Drug Metab. 13(7), 901-910 (2012).
21. Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, an HER2 Antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28(16), 2698-2704 (2010).
22. Gupta M, Lorusso PM, Wang B et al. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J. Clin. Pharmacol. 52(5), 691-703 (2012).
23. Junttila TT, Li G, Parsons K et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 128, 347-356 (2011).
24. Kovtun YV, Audette CA, Mayo MF et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 70(6), 2528-2537 (2010).
25. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 49(10), 633-659 (2010).
26. Lee JI, Zhang L, Men AY, Kenna LA, Huang SM. CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin. Pharmacokinet. 49(5), 295-310 (2010).
27. Huang SM, Zhao H, Lee JI et al. Therapeutic protein-drug interactions and implications for drug development. Clin. Pharmacol. Ther. 87(4), 497-503 (2010).
28. Seitz K, Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J. Clin. Pharmacol. 47(9), 1104-1118 (2007).
29. Zhou H, Davis HM. Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov. Today 14(17-18), 891-898 (2009).
30. Mahmood I, Green MD. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J. Clin. Pharmacol. 47(12), 1540-1554 (2007).
31. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin. Pharmacol. Ther. 85(4), 434-438 (2009).
32. Zhou H, Mascelli MA. Mechanisms of monoclonal antibody-drug interactions. Annu. Rev. Pharmacol. Toxicol. 51, 359-372 (2011).
33. Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfa E. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin. Rev. Allergy Immunol. 38(2-3), 82-89 (2010).
34. Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J. Rheumatol. 33(1), 31-36 (2006).
35. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66(7), 921-926 (2007).
36. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41(9), 1552-1563 (1998).
37. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56(9), 1226-1231 (2007).
38. Humira™ (adalimumab), package insert. Abbott Laboratories, Chicago, IL, USA.
39. Joshi A, Bauer R, Kuebler P et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J. Clin. Pharmacol. 46(1), 10-20 (2006).
40. Vincenti F, Mendez R, Pescovitz M et al. A Phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am. J. Transplant. 7(7), 1770-1777 (2007).
41. Girish S, Martin SW, Peterson MC et al. AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development. AAPS J. 13(3), 405-416 (2011).
42. Lu D, Joshi A, Agarwal P et al. Assessment of drug interaction potential of an antibody drug conjugate with other therapeutic agents: case studies of trastuzumab emtansine (T-DM1) in combination with pertuzumab or taxane. Presented at: American Society of Clinical Pharmacology and Therapeutics Annual Meeting. National Harbor, MD, USA, 12-17 March 2012.
43. Shen BQ, Xu K, Liu L et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 30(2), 184-189 (2012).
44. Erickson HK, Park PU, Widdison WC et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66(8), 4426-4433 (2006).
45. Alley SC, Zhang X, Okeley NM et al. The pharmacologic basis for antibody-auristatin conjugate activity. J. Pharmacol. Exp. Ther. 330(3), 932-938 (2009).
46. Kovtun YV, Audette CA, Mayo MF et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 70(6), 2528-2537 (2010).
47. Okeley NM, Miyamoto JB, Zhang X et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin. Cancer Res. 16(3), 888-897 (2010).
48. Wong S, Bumbaca D, Yue Q et al. Nonclinical disposition, metabolism and in vitro drug interaction assessment of DM1, a component of trastuzumab emtansine (T-DM1). Presented at: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. San Francisco, CA, USA, November 2011.
49. Toppmeyer DL, Slapak CA, Croop J, Kufe DW. Role of P-glycoprotein in dolastatin 10 resistance. Biochem. Pharmacol. 48(3), 609-612 (1994).
50. Takeshita A, Shinjo K, Yamakage N et al. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br. J. Haematol. 146(1), 34-43 (2009).
51. Taxol® (paclitaxel), packet insert. Bristol-Myers Squibb Co., Princeton, NJ, USA.
52. Taxotere®(docetaxel), package insert. Sanofi-Aventis, Bridgewater, NJ, USA.
53. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. The Simcyp® population-based ADME simulator. Expert Opin. Drug Metab. Toxicol. 5(2), 211-223 (2009).
54. Morrissey KM, Wen CC, Johns SJ, Zhang L. The UCSF-FDA TransPortal: a public drug transporter database. Clin. Pharmacol. Ther. 92(5), 545-546 (2012).
55. Burris HA 3rd, Rugo HS, Vukelja SJ et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 29(4), 398-405 (2011).
56. Krop IE, LoRusso P, Miller KD et al. A Phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 30(26), 3234-41 (2012).
57. Lu D, Modi S, Elias A et al. Pharmacokinetics (PK) of trastuzumab emtansine and paclitaxel or docetaxel in patients with HER2-positive metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen. Presented at: 34th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 6-10 December 2011.
58. Mross K, Haring B, Hollander N et al. Comparison of 1-hour and 3-hours paclitaxel pharmacokinetics: results from a randomized trial. Onkologie 25(6), 503-508 (2002).
59. Lu D, Krop IE, Modi S et al. Pharmacokinetics (PK) of trastuzumab-DM1 (T-DM1) and paclitaxel (T) in patients with HER2+ locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen. Presented at: 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2010.
60. US FDA. Clinical pharmacology and biopharmaceutics review(s) for brentuximab vedotin.www.accessdata.fda.gov/drugsatfda-docs/nda/2011/ 125388Orig1s000ClinPharmR.pdf(Accessed 9 January 2013)
61. US FDA. Guidelines for exposure-response analysis of drugs.www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072109. pdf(Accessed 12 March 2013)
62. US FDA. Guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling. Draft guidance. www.fda.gov/downloads/Drugs/plianceRegulatoryInformation/Guidances/UCM292362. pdf (Accessed 9 January 2013)
63. European Medicines Agency. Guideline on the investigation of drug interactions.www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2010/05/WC500090112.pdf (Accessed 12 October 2011)
64. US FDA. Pharmacology review(s) for brentuximab vedotin. www.accessdata.fda.gov/drugsatfda-docs/nda/2011/125388Orig1s000PharmR.pdf (Accessed 9 January 2013)